NM-2-AI Stats & Data

Evidence-based harm-reduction additions and clarifications: 1) Batch variability and weak stand‑alone effects are frequently reported; treat each new source as unknown potency and begin with a low test dose. 2) Redosing can increase blood pressure/heart rate without adding much euphoria—avoid chasing effects and wait at least 90–120 minutes before considering any redose. 3) Oral administration avoids the pronounced nasal causticity many users report when snorting; if insufflating, finely crush, use small lines spaced apart, alternate nostrils, and rinse with isotonic saline to reduce damage. 4) Avoid combining with other stimulants (including high caffeine) or with alcohol; such mixes increase strain on the cardiovascular system and can mask impairment. 5) Absolutely avoid MAOIs; use strong caution with SNRIs/SSRIs due to unpredictable serotonergic modulation and with seizure‑threshold–lowering drugs (e.g., bupropion, tramadol). 6) Measure doses with a milligram‑accurate scale or use volumetric dosing; do not eyeball powders. 7) Because onset may be delayed up to ~1 hour, premature redosing increases risk of over‑stimulation. 8) Monitor for irritability, anxiety, headache, or mood drop; these are reported at higher doses or with repeated use—post‑use rest, nutrition, and hydration help recovery. 9) Use drug checking whenever possible; reagent and especially lab drug‑checking services help detect mislabeling or adulterants. 10) As with other stimulants, maintain moderate hydration, take cooling breaks in hot environments, and avoid strenuous activity during peaks. 11) Do not drive or operate machinery while under effects or during the residual phase; sleep can be fragmented despite perceived fatigue.